Onco-Innovations Stock Price, News & Analysis

Onco-Innovations (OTCQB:ONNVF) has announced a non-brokered private placement to raise up to $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit includes one common share and one warrant, with warrants exercisable at $2.05 for 36 months.

The company will issue additional shares as a 1% administrative fee to a third party. Additionally, Onco-Innovations has approved the grant of 119,785 stock options and 960,000 restricted share units (RSUs) under its equity incentive plan. The proceeds will support general corporate purposes and R&D objectives.

Onco-Innovations (CBOE CA:ONCO) has appointed renowned chemist Dr. Dennis Hall to its Scientific and Clinical Advisory Board. Dr. Hall, a Professor of Chemistry at the University of Alberta and Tier 1 Canada Research Chair in Boron Chemistry, brings extensive expertise in organoboron chemistry, catalysis, and medicinal chemistry.

Dr. Hall's impressive credentials include over 175 peer-reviewed publications, 18,000+ citations, and numerous prestigious awards. He will provide strategic guidance on the company's R&D initiatives, particularly focusing on the development of PNKP Inhibitor Technology NP/A83 for oncology applications.

Onco-Innovations (OTCQB:ONNVF) has entered into a services agreement with Redwood AI to advance the development of its exclusively-licensed Polynucleotide Kinase Phosphatase (PNKP) Compound technology. The collaboration aims to enhance the company's drug development capabilities through AI-driven chemistry tools.

The partnership will leverage Redwood AI's expertise in synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the PNKP technology. The proprietary compound targets solid tumors by increasing sensitivity to radiation and DNA-damaging chemotherapies. This strategic collaboration is designed to support Onco's progression toward First-in-Human studies by improving scalability, safety, and discovery precision.

Onco-Innovations (CBOE CA:ONCO) has appointed Dr. Islam Mohamed as Chair of its Scientific and Clinical Advisory Board. Dr. Mohamed brings over 20 years of experience as a Radiation Oncologist, clinical researcher, and biotechnology advisor.

Dr. Mohamed's expertise spans lung, breast, skin cancers, and sarcoma treatment at BC Cancer, with significant experience in stereotactic radiation delivery. He has led numerous clinical trials and served on research ethics boards and national committees. His role will involve providing strategic guidance on R&D initiatives and facilitating clinical and scientific collaboration.

Onco-Innovations (OTCQB:ONNVF) has signed a crucial agreement with Nucro-Technics to conduct IND-enabling preclinical studies for its lead drug candidate. The studies will focus on the company's PNKP inhibitor (NP/A83), which targets advanced-stage, PTEN- or SHP-1-deficient cancers.

The comprehensive testing program includes drug metabolism testing (ADME studies) and GLP-compliant safety studies required for regulatory approval. Nucro-Technics, a Toronto-based CRO with 55 years of experience, will evaluate the drug's bioavailability, biodistribution, pharmacokinetics, and safety profile to support future IND applications with both FDA and Health Canada.

The agreement represents a significant milestone toward initiating Phase I/II clinical trials, including validation of analytical methods and safety assessment of the novel polymer delivery system (mPEO-bPBCL).

Onco-Innovations (OTCQB:ONNVF) CEO Thomas O'Shaughnessy provided a comprehensive update on the company's strategic developments and R&D progress during a special investor call. Key highlights include the advancement of their PNKP Inhibitor Technology with Dalton Pharma Services for preclinical testing, and progress in the PROmAI consortium with potential AstraZeneca participation.

The company has established a new research agreement with the University of Alberta and Cross Cancer Institute to study PNKP inhibition in glioblastoma multiforme. Following their February 2025 acquisition of Inka Health AI and May 2025 uplisting to Cboe Canada, Onco-Innovations continues to integrate AI capabilities into drug development through Inka's Synograph system.

Onco-Innovations (CBOE CA:ONCO) announced that its subsidiary, Inka Health, has received an Expression of Interest (EOI) from AstraZeneca to join as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium.

The PROmAI Consortium, led by Inka Health, aims to advance AI methodologies in oncology by combining real-world and clinical trial data with causal AI techniques. The initiative focuses on improving predictive modeling in cancer research, particularly during the transition from early- to late-phase clinical development.

AstraZeneca's involvement will include participation in the exploratory phase, encompassing joint planning discussions, project direction input, and strategic alignment around key use cases. Inka Health is currently in discussions with other global pharmaceutical companies for potential consortium participation.

Onco-Innovations Limited (OTCQB:ONNVF) has announced a special investors' conference call scheduled for Wednesday, July 2, 2025, at 2:00 p.m. PST/5:00 p.m. ET. The call will be hosted by CEO Thomas O'Shaughnessy.

Investors can participate through the conference link's 'Dial Me' feature or by calling toll-free numbers. Participants are encouraged to submit questions in advance to investors@oncoinnovations.com. The company will release a press release following the conference call.

Onco-Innovations Limited announced that co-founders of its subsidiary Inka Health Corp. published a study examining the applicability of lung cancer clinical trial outcomes to real-world populations. The study, titled 'Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations,' demonstrated strong predictive performance with less than 1% variation in matching real-world outcomes over 30 months. The research supports the development of SynoGraph, Inka Health's causal AI platform, which aims to enhance drug development through real-world analytics. The study's methodology focuses on optimizing trial design and defining relevant populations to reduce development pipeline risks.